Cingulate

Yahoo Finance • last year

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING)... Full story

Yahoo Finance • last year

Cingulate to Host CNS Key Opinion Leader Panel in New York City

KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • last year

Cingulate Announces Closing of $4.0 Million Public Offering

KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery pl... Full story

Yahoo Finance • last year

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend Toward Significance Treatment Effect Size... Full story

Yahoo Finance • last year

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance... Full story

Yahoo Finance • last year

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline... Full story

Yahoo Finance • last year

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Werth Family Investment Associates Provides Additional Capital Investment Phase 3 Adult Efficacy and Safety Trial of CTx-1301 Data Released CTx-1301 Phase 3 Pediatric and Adolescent Studies Underway KANSAS CITY, Kan., Aug. 14, 2023 (GLO... Full story

Yahoo Finance • last year

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) --... Full story

Yahoo Finance • 2 years ago

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline... Full story

Yahoo Finance • 2 years ago

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utiliz... Full story

Yahoo Finance • 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming Medical Meeting CTx-1301 Pivotal Phase... Full story

Yahoo Finance • 2 years ago

Cingulate stock skyrockets after ADHD treatment shows positive trial results

Shares of Cingulate Inc. (CING) skyrocketed 82.9% toward an 11-month high in active premarket trading Friday, after the biopharmaceutical company reported positive results from a trial of its attention deficit/hyperactivity disorder (ADHD)... Full story

Yahoo Finance • 2 years ago

Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biophar... Full story

Yahoo Finance • 2 years ago

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story

Yahoo Finance • 2 years ago

Cingulate to Present at LD Micro Investor Conference

KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline o... Full story